Posted by Michael Wonder on 14 Sep 2022
Growing financial burden from high-cost targeted oral anti-cancer medicines among Medicare beneficiaries with cancer
13 September 2022 - The rapidly rising costs of targeted oral anti-cancer medicines raise concerns over their affordability.
Our goal was to examine recent trends in the uptake of targeted oral anti-cancer medicines among cancer patients with Medicare Part D, the share of targeted oral anti-cancer medicine users who reached catastrophic coverage, and the annual spending on targeted oral anti-cancer medicines in the catastrophic phase.
